Sandbox:Cancer screening and primary care: Difference between revisions

Jump to navigation Jump to search
Line 3: Line 3:


==Overview==
==Overview==
== Epidemiology ==
The most common type of cancer, excluding non-melanoma skin cancers is breast cancer, with more than 249,000 new cases expected in the United States in 2016. The next most common cancers are lung cancer and prostate cancer. In United states, to qualify as a common cancer, the estimated annual incidence for 2016 had to be 40,000 cases or more.
The following table gives the estimated numbers of new cases and deaths in Unites states for each common cancer type: <ref>American Cancer Society. Cancer Facts & Figures 2016. Atlanta: American Cancer Society; 2016</ref>
{| class="wikitable"
! colspan="3" |American Cancer Society. Cancer Facts & Figures 2016
|-
!Cancer Type
!Estimated New Cases
!Estimated Deaths
|-
|[[Breast cancer epidemiology and demographics|Breast]]
|249,200
|40,890
|-
|[[Lung cancer epidemiology and demographics|Lung (Including Bronchus)]]
|224,390
|158,080
|-
|[[Prostate cancer epidemiology and demographics|Prostate]]
|180,890
|26,120
|-
|[[Colorectal cancer epidemiology and demographics|Colon and Rectal (Combined)]]
|134,490
|49,190
|-
|[[Bladder cancer epidemiology and demographics|Bladder]]
|76,960
|16,390
|-
|[[Melanoma epidemiology and demographics|Melanoma]]
|76,380
|10,130
|-
|[[Non-Hodgkin Lymphoma]]
|72,580
|20,150
|-
|[[Thyroid cancer|Thyroid]]
|64,300
|1,980
|-
|[[Kidney Cancer|Kidney (Renal Cell and Renal Pelvis) Cancer]]
|62,700
|14,240
|-
|[[Leukemia epidemiology and demographics|Leukemia (All Types)]]
|60,140
|24,400
|-
|[[Endometrial cancer epidemiology and demographics|Endometrial]]
|60,050
|10,470
|-
|[[Pancreatic cancer epidemiology and demographics|Pancreatic]]
|53,070
|41,780
|}
===Adult Cancers===
In the U.S. and other developed countries, cancer is presently responsible for about 25% of all deaths.<ref name="CACancerJClin2005-Jemal">{{cite journal | author=Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ | title=Cancer statistics, 2005 | journal=CA Cancer J Clin | year=2005 | pages=10-30 | volume=55 | issue=1 | url=http://caonline.amcancersoc.org/cgi/content/full/55/1/10 | id=PMID 15661684}}</ref> On a yearly basis, 0.5% of the population is diagnosed with cancer. The statistics below are for adults in the United States, and may vary substantially in other countries:
{| class="wikitable"
! colspan="2" |<big>Male</big>
! colspan="2" |<big>Female</big>
|-
! width="170px" |most common (by occurrence)!! width="170px" |most common (by mortality) <ref name="CACancerJClin2005-Jemal" />
! width="170px" |most common (by occurrence)!! width="170px" |most common (by mortality) <ref name="CACancerJClin2005-Jemal" />
|-
|[[prostate cancer]] (33%)||lung cancer (31%)||[[breast cancer]] (32%)||lung cancer (27%)
|-
|[[lung cancer]] (13%)||prostate cancer (10%)||lung cancer (12%)||breast cancer (15%)
|-
|[[colorectal cancer]] (10%)||colorectal cancer (10%)||colorectal cancer (11%)||colorectal cancer (10%)
|-
|[[bladder cancer]] (7%)||[[pancreatic cancer]] (5%)||[[endometrial cancer]] (6%)||[[ovarian cancer]] (6%)
|-
|cutaneous [[melanoma]] (5%)||[[leukemia]] (4%)||[[non-Hodgkin lymphoma]] (4%)||pancreatic cancer (6%)
|}
===Childhood Cancers===
Cancer can also occur in young children and adolescents, but it is rare (about 150 cases per million yearly in the US). Statistics from the SEER program of the US [[National Cancer Institute|NCI]] demonstrate that childhood cancers increased 19% between 1975 and 1990, mainly due to an increased incidence in [[acute leukemia]]. Since 1990, incidence rates have decreased <ref>''Cancer Incidence and Survival among Children and Adolescents, United States SEER program 1975-1995'', available online from the [http://www.seer.cancer.gov/publications/childhood/ SEER web site]</ref>
The age of peak incidence of cancer in children occurs during the first year of life. [[Leukemia]] (usually [[Acute lymphoblastic leukemia|ALL]]) is the most common infant malignancy (30%), followed by the [[Brain tumor|central nervous system cancers]] and [[neuroblastoma]]. The remainder consists of [[Wilms' tumor]], [[lymphoma]]s, [[rhabdomyosarcoma]] (arising from muscle), [[retinoblastoma]], [[osteosarcoma]] and [[Ewing's sarcoma]].<ref name="CACancerJClin2005-Jemal" /> [[Teratoma]] is the most common tumor in this age group, but most teratomas are surgically removed while still benign, hence not necessarily cancer.
Female and male infants have essentially the same overall cancer incidence rates, but white infants have substantially higher cancer rates than black infants for most cancer types. Relative survival for infants is very good for neuroblastoma, [[Wilms' tumor]] and [[retinoblastoma]], and fairly good (80%) for leukemia, but not for most other types of cancer.
==Screening==
==Screening==
===Breast Cancer===
====Breast Cancer====
{| class="wikitable"
{| class="wikitable"
! colspan="3" |United states preventive services task force recommendations for Breast cancer screening
! colspan="3" |United states preventive services task force recommendations for Breast cancer screening
Line 31: Line 116:
Studies have reported that, for women of all age groups with an average risk, ''breast screening'' was associated with a reduction in breast cancer mortality of approximately 20%, although there was an uncertainty in the quantitative estimates of outcomes for different breast cancer screening strategies in the United States.<ref name="pmid2650153722">{{cite journal| author=Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S et al.| title=Benefits and Harms of Breast Cancer Screening: A Systematic Review. | journal=JAMA | year= 2015 | volume= 314 | issue= 15 | pages= 1615-34 | pmid=26501537 | doi=10.1001/jama.2015.13183 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26501537  }}  [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26974726 Review in: Ann Intern Med. 2016 Mar 15;164(6):JC26]</ref>
Studies have reported that, for women of all age groups with an average risk, ''breast screening'' was associated with a reduction in breast cancer mortality of approximately 20%, although there was an uncertainty in the quantitative estimates of outcomes for different breast cancer screening strategies in the United States.<ref name="pmid2650153722">{{cite journal| author=Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S et al.| title=Benefits and Harms of Breast Cancer Screening: A Systematic Review. | journal=JAMA | year= 2015 | volume= 314 | issue= 15 | pages= 1615-34 | pmid=26501537 | doi=10.1001/jama.2015.13183 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26501537  }}  [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26974726 Review in: Ann Intern Med. 2016 Mar 15;164(6):JC26]</ref>


'''Please''' [[Breast cancer screening|click here]] to know more about ''[[breast cancer screening]]''
'''Please [[Breast cancer screening|click here]] to know more about ''[[breast cancer screening]]'''''
===Colon cancer===
===Colon cancer===
{| class="wikitable"
{| class="wikitable"
Line 53: Line 138:
Studies have reported, 40% to 60% lower risk of incident colorectal cancer and mortality from colorectal cancer after screening colonoscopy.<ref name="pmid249227452">{{cite journal| author=Brenner H, Stock C, Hoffmeister M| title=Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. | journal=BMJ | year= 2014 | volume= 348 | issue=  | pages= g2467 | pmid=24922745 | doi=10.1136/bmj.g2467 | pmc=3980789 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24922745  }}</ref>
Studies have reported, 40% to 60% lower risk of incident colorectal cancer and mortality from colorectal cancer after screening colonoscopy.<ref name="pmid249227452">{{cite journal| author=Brenner H, Stock C, Hoffmeister M| title=Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. | journal=BMJ | year= 2014 | volume= 348 | issue=  | pages= g2467 | pmid=24922745 | doi=10.1136/bmj.g2467 | pmc=3980789 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24922745  }}</ref>


'''Please''' [[Colorectal cancer screening|click here]] to know more about [[Colorectal cancer screening|''Colon cancer screening'']]''.''
'''Please [[Colorectal cancer screening|click here]] to know more about [[Colorectal cancer screening|''Colon cancer screening'']]''.'''''
===[[Cervical cancer]]===
==='''Cervical cancer'''===
{| class="wikitable"
{| class="wikitable"
! colspan="3" |United states preventive services task force recommendations for Cervical cancer screening
! colspan="3" |United states preventive services task force recommendations for Cervical cancer screening
Line 69: Line 154:
Studies have reported, that in patients undergoing regular cervical cancer, approximately 70%-80% of cervical cancer deaths can be prevented.<ref name="pmid27632376">{{cite journal| author=Landy R, Pesola F, Castañón A, Sasieni P| title=Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. | journal=Br J Cancer | year= 2016 | volume= 115 | issue= 9 | pages= 1140-1146 | pmid=27632376 | doi=10.1038/bjc.2016.290 | pmc=5117785 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27632376  }}</ref>
Studies have reported, that in patients undergoing regular cervical cancer, approximately 70%-80% of cervical cancer deaths can be prevented.<ref name="pmid27632376">{{cite journal| author=Landy R, Pesola F, Castañón A, Sasieni P| title=Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. | journal=Br J Cancer | year= 2016 | volume= 115 | issue= 9 | pages= 1140-1146 | pmid=27632376 | doi=10.1038/bjc.2016.290 | pmc=5117785 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27632376  }}</ref>


'''Please''' [[Cervical cancer screening|click here]] to know more about [[Cervical cancer screening|''Cervical cancer screening'']]''.''
'''Please [[Cervical cancer screening|click here]] to know more about [[Cervical cancer screening|''Cervical cancer screening'']]''.'''''


=== Lung cancer ===
=== Lung cancer ===
Line 87: Line 172:
National lung screen trial (nlst) a randomized controlled trial, involving 50,000 participants as demonstrated a 20% relative lung cancer mortality benefit.<ref name="pmid21714641">{{cite journal| author=National Lung Screening Trial Research Team. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD et al.| title=Reduced lung-cancer mortality with low-dose computed tomographic screening. | journal=N Engl J Med | year= 2011 | volume= 365 | issue= 5 | pages= 395-409 | pmid=21714641 | doi=10.1056/NEJMoa1102873 | pmc=4356534 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21714641  }}  [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22084353 Review in: Ann Intern Med. 2011 Nov 15;155(10):JC5-06]</ref>
National lung screen trial (nlst) a randomized controlled trial, involving 50,000 participants as demonstrated a 20% relative lung cancer mortality benefit.<ref name="pmid21714641">{{cite journal| author=National Lung Screening Trial Research Team. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD et al.| title=Reduced lung-cancer mortality with low-dose computed tomographic screening. | journal=N Engl J Med | year= 2011 | volume= 365 | issue= 5 | pages= 395-409 | pmid=21714641 | doi=10.1056/NEJMoa1102873 | pmc=4356534 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21714641  }}  [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22084353 Review in: Ann Intern Med. 2011 Nov 15;155(10):JC5-06]</ref>


Please [[Lung cancer screening|click here]] to know more about ''[[Lung cancer screening]].''
'''Please [[Lung cancer screening|click here]] to know more about ''[[Lung cancer screening]].'''''
 
==Epidemiology==
The most common type of cancer, excluding non-melanoma skin cancers is breast cancer, with more than 249,000 new cases expected in the United States in 2016. The next most common cancers are lung cancer and prostate cancer. In United states, to qualify as a common cancer, the estimated annual incidence for 2016 had to be 40,000 cases or more.
 
The following table gives the estimated numbers of new cases and deaths in Unites states for each common cancer type: <ref>American Cancer Society. Cancer Facts & Figures 2016. Atlanta: American Cancer Society; 2016</ref>
{| class="wikitable"
! colspan="3" |American Cancer Society. Cancer Facts & Figures 2016
|-
!Cancer Type
!Estimated New Cases
!Estimated Deaths
|-
|[[Breast cancer epidemiology and demographics|Breast]]
|249,200
|40,890
|-
|[[Lung cancer epidemiology and demographics|Lung (Including Bronchus)]]
|224,390
|158,080
|-
|[[Prostate cancer epidemiology and demographics|Prostate]]
|180,890
|26,120
|-
|[[Colorectal cancer epidemiology and demographics|Colon and Rectal (Combined)]]
|134,490
|49,190
|-
|[[Bladder cancer epidemiology and demographics|Bladder]]
|76,960
|16,390
|-
|[[Melanoma epidemiology and demographics|Melanoma]]
|76,380
|10,130
|-
|[[Non-Hodgkin Lymphoma]]
|72,580
|20,150
|-
|[[Thyroid cancer|Thyroid]]
|64,300
|1,980
|-
|[[Kidney Cancer|Kidney (Renal Cell and Renal Pelvis) Cancer]]
|62,700
|14,240
|-
|[[Leukemia epidemiology and demographics|Leukemia (All Types)]]
|60,140
|24,400
|-
|[[Endometrial cancer epidemiology and demographics|Endometrial]]
|60,050
|10,470
|-
|[[Pancreatic cancer epidemiology and demographics|Pancreatic]]
|53,070
|41,780
|}


==Genetics==
==Genetics==
==References==
==References==
<references />__NOTOC__
<references />__NOTOC__

Revision as of 21:18, 1 February 2017

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Vishal Devarkonda, M.B.B.S[2]

Overview

Epidemiology

The most common type of cancer, excluding non-melanoma skin cancers is breast cancer, with more than 249,000 new cases expected in the United States in 2016. The next most common cancers are lung cancer and prostate cancer. In United states, to qualify as a common cancer, the estimated annual incidence for 2016 had to be 40,000 cases or more.

The following table gives the estimated numbers of new cases and deaths in Unites states for each common cancer type: [1]

American Cancer Society. Cancer Facts & Figures 2016
Cancer Type Estimated New Cases Estimated Deaths
Breast 249,200 40,890
Lung (Including Bronchus) 224,390 158,080
Prostate 180,890 26,120
Colon and Rectal (Combined) 134,490 49,190
Bladder 76,960 16,390
Melanoma 76,380 10,130
Non-Hodgkin Lymphoma 72,580 20,150
Thyroid 64,300 1,980
Kidney (Renal Cell and Renal Pelvis) Cancer 62,700 14,240
Leukemia (All Types) 60,140 24,400
Endometrial 60,050 10,470
Pancreatic 53,070 41,780

Adult Cancers

In the U.S. and other developed countries, cancer is presently responsible for about 25% of all deaths.[2] On a yearly basis, 0.5% of the population is diagnosed with cancer. The statistics below are for adults in the United States, and may vary substantially in other countries:

Male Female
most common (by occurrence) most common (by mortality) [2] most common (by occurrence) most common (by mortality) [2]
prostate cancer (33%) lung cancer (31%) breast cancer (32%) lung cancer (27%)
lung cancer (13%) prostate cancer (10%) lung cancer (12%) breast cancer (15%)
colorectal cancer (10%) colorectal cancer (10%) colorectal cancer (11%) colorectal cancer (10%)
bladder cancer (7%) pancreatic cancer (5%) endometrial cancer (6%) ovarian cancer (6%)
cutaneous melanoma (5%) leukemia (4%) non-Hodgkin lymphoma (4%) pancreatic cancer (6%)

Childhood Cancers

Cancer can also occur in young children and adolescents, but it is rare (about 150 cases per million yearly in the US). Statistics from the SEER program of the US NCI demonstrate that childhood cancers increased 19% between 1975 and 1990, mainly due to an increased incidence in acute leukemia. Since 1990, incidence rates have decreased [3]

The age of peak incidence of cancer in children occurs during the first year of life. Leukemia (usually ALL) is the most common infant malignancy (30%), followed by the central nervous system cancers and neuroblastoma. The remainder consists of Wilms' tumor, lymphomas, rhabdomyosarcoma (arising from muscle), retinoblastoma, osteosarcoma and Ewing's sarcoma.[2] Teratoma is the most common tumor in this age group, but most teratomas are surgically removed while still benign, hence not necessarily cancer.

Female and male infants have essentially the same overall cancer incidence rates, but white infants have substantially higher cancer rates than black infants for most cancer types. Relative survival for infants is very good for neuroblastoma, Wilms' tumor and retinoblastoma, and fairly good (80%) for leukemia, but not for most other types of cancer.

Screening

Breast Cancer

United states preventive services task force recommendations for Breast cancer screening
Population Recommendation Grade
Women, 40 Years and Older The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of clinical breast examination (CBE) beyond screening mammography in women 40 years or older. I
Women, Age 50-74 Years The USPSTF recommends biennial screening mammography for women 50-74 years. B
Women, Before the Age of 50 Years The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms. C
Women, 75 Years and Older The USPSTF concludes that the current evidence is insufficient to assess the benefits and harms of screening mammography in women 75 years and older. I

Breast cancer screening relevance

Studies have reported that, for women of all age groups with an average risk, breast screening was associated with a reduction in breast cancer mortality of approximately 20%, although there was an uncertainty in the quantitative estimates of outcomes for different breast cancer screening strategies in the United States.[4]

Please click here to know more about breast cancer screening

Colon cancer

United states preventive services task force recommendations for Colon cancer screening
Population Recommendation Grade
Adults aged 50 to 75 years The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years. A
Adults aged 76 to 85 years The decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patient’s overall health and prior screening history.
  • Adults in this age group who have never been screened for colorectal cancer are more likely to benefit.
  • Screening would be most appropriate among adults who 1) are healthy enough to undergo treatment if colorectal cancer is detected and 2) do not have comorbid conditions that would significantly limit their life expectancy.
C

Colon cancer screening relevance

Studies have reported, 40% to 60% lower risk of incident colorectal cancer and mortality from colorectal cancer after screening colonoscopy.[5]

Please click here to know more about Colon cancer screening.

Cervical cancer

United states preventive services task force recommendations for Cervical cancer screening
Population Recommendation Grade
Women 21 to 65 (Pap Smear) or 30-65 (in combo with HPV testing) The USPSTF recommends screening for cervical cancer in women age 21 to 65 years with cytology (Pap smear) every 3 years or, for women age 30 to 65 years who want to lengthen the screening interval, screening with a combination of cytology and human papillomavirus (HPV) testing every 5 years. A

Cervical cancer screening relevance

Studies have reported, that in patients undergoing regular cervical cancer, approximately 70%-80% of cervical cancer deaths can be prevented.[6]

Please click here to know more about Cervical cancer screening.

Lung cancer

United states preventive services task force recommendations for Lung cancer screening
Population Recommendation Grade
Adults Aged 55-80, with a History of Smoking The USPSTF recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. B

Lung caner screening relevance

National lung screen trial (nlst) a randomized controlled trial, involving 50,000 participants as demonstrated a 20% relative lung cancer mortality benefit.[7]

Please click here to know more about Lung cancer screening.

Genetics

References

  1. American Cancer Society. Cancer Facts & Figures 2016. Atlanta: American Cancer Society; 2016
  2. 2.0 2.1 2.2 2.3 Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005). "Cancer statistics, 2005". CA Cancer J Clin. 55 (1): 10–30. PMID 15661684.
  3. Cancer Incidence and Survival among Children and Adolescents, United States SEER program 1975-1995, available online from the SEER web site
  4. Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S; et al. (2015). "Benefits and Harms of Breast Cancer Screening: A Systematic Review". JAMA. 314 (15): 1615–34. doi:10.1001/jama.2015.13183. PMID 26501537. Review in: Ann Intern Med. 2016 Mar 15;164(6):JC26
  5. Brenner H, Stock C, Hoffmeister M (2014). "Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies". BMJ. 348: g2467. doi:10.1136/bmj.g2467. PMC 3980789. PMID 24922745.
  6. Landy R, Pesola F, Castañón A, Sasieni P (2016). "Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study". Br J Cancer. 115 (9): 1140–1146. doi:10.1038/bjc.2016.290. PMC 5117785. PMID 27632376.
  7. National Lung Screening Trial Research Team. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD; et al. (2011). "Reduced lung-cancer mortality with low-dose computed tomographic screening". N Engl J Med. 365 (5): 395–409. doi:10.1056/NEJMoa1102873. PMC 4356534. PMID 21714641. Review in: Ann Intern Med. 2011 Nov 15;155(10):JC5-06